The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J02 | Antimycotics for systemic use | |
| 3 | J02A | Antimycotics for systemic use | |
| 4 | J02AX | Other antimycotics for systemic use | |
| 5 | J02AX08 |
| Active Ingredient | Description | |
|---|---|---|
| Rezafungin |
Rezafungin selectively inhibits fungal 1,3-β-D-glucan synthase. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall which is not present in mammalian cells. Inhibition of 1,3-β-D-glucan synthesis results in rapid and concentration-dependent fungicidal activity in Candida species (spp.). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| REZZAYO Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| REZZAYO Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
